%0 Journal Article
%T Monitoring blood biomarkers to predict nivolumab effectiveness in
NSCLC patients
%A Alessandro Perez
%A Angela List¨¬
%A Antonio Galvano
%A Antonio Russo
%A Francesco Passiglia
%A Giuseppe Gallina
%A Hector Soto Parra
%A Lorena Incorvaia
%A Marta Castiglia
%A Salvatore Mazzarisi
%A Sergio Rizzo
%A Valentina Cal¨°
%A Viviana Bazan
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919839928
%X We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC)
%K blood-based biomarkers
%K Circulating free DNA (cfDNA)
%K immunotherapy
%K neutrophil to lymphocyte ratio (NLR)
%K non-small cell lung cancer (NSCLC)
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469277/